|By Business Wire||
|June 17, 2014 05:51 PM EDT||
A study published Thursday in the Oxford Journal Neuro-Oncology, ‘Navigated transcranial magnetic stimulation improves the treatment outcome in patients with brain tumors in motor eloquent areas’, looked at the outcomes of 365 motor eloquent brain-tumor patients. The study proved that integrating navigated transcranial magnetic stimulation (nTMS) into the surgical workflow to pre-operatively localize motor function has a significant impact on treatment and outcome.
The authors from Charité University in Berlin, looked at using Nexstim’s Navigated Brain Stimulation (NBS) System for pre-operative motor mapping. The study enrolled 250 consecutive patients and compared their outcomes to a matched pre-nTMS control group on 115 patients. The results of the NBS mapping impacted the surgical plan in 68% of the cases:
- Disproving suspected involvement of the primary motor cortex in 25.1% of the cases
- Expanded surgical indication by 14.8%
- Achieved 18% more total resections
- Progression free survival increased by 45% in patients with low grade gliomas
“This is why we work to get this amazing technology to the clinics. Helping patients to get better care and provide neurosurgeons more tools for their important pre-operative planning is driving us further.” – Janne Huhtala, CEO, Nexstim
In their conclusions, the authors stated “the impact of this study should go far beyond the neurosurgical community because it could fundamentally improve treatment and outcome, and its results will likely change clinical practice.” The use of NBS for pre-surgical mapping provided crucial data that improved surgical planning and patient communication. nTMS has now been proven to enable more patients to undergo surgery, which in turn may lead to better neurological outcomes and higher survival rates in brain tumor patients.
Founded in Finland in 2000, Nexstim is the world leader in image-guided transcranial magnetic stimulation (TMS). The company is committed to improving the quality of life of patients. Nexstim has pioneered the technology for brain diagnostics with the Navigated Brain Stimulation (NBS) System as the first and only FDA-cleared and CE-marked navigated TMS (nTMS) device for pre-surgical mapping of the motor and speech cortices. The advanced technology providing navigation to TMS has led NBS to be recognized as the emerging standard for pre-operative direct functional mapping.
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Aug. 28, 2015 11:45 PM EDT Reads: 393
Aug. 28, 2015 11:30 PM EDT Reads: 817
Aug. 28, 2015 09:00 PM EDT Reads: 285
Aug. 28, 2015 07:45 PM EDT Reads: 158
Aug. 28, 2015 06:00 PM EDT Reads: 307
Aug. 28, 2015 05:45 PM EDT Reads: 453
Aug. 28, 2015 05:30 PM EDT Reads: 403
Aug. 28, 2015 03:45 PM EDT Reads: 167
Aug. 28, 2015 03:15 PM EDT
Aug. 28, 2015 03:01 PM EDT
Aug. 28, 2015 02:15 PM EDT Reads: 408
Aug. 28, 2015 02:00 PM EDT
Aug. 28, 2015 12:30 PM EDT Reads: 116
Aug. 28, 2015 12:30 PM EDT Reads: 144
Aug. 28, 2015 12:30 PM EDT